- Article
Predicting Factors of Plasma HIV RNA Undetectability after Switching to Co-Formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Experienced HIV-1 Patients: A Multicenter Study
- Monica Basso,
- Giuliana Battagin,
- Stefano Nicolè,
- Maria Cristina Rossi,
- Francesco Colombo,
- Nicole Pirola,
- Stefano Baratti,
- Silvia Storato,
- Federico Giovagnorio and
- Saverio Giuseppe Parisi
- + 5 authors
Switching to bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) from other antiretroviral regimens is safe and effective for virologically suppressed people living with HIV (PLWH). The term virological suppression includes both low b...